OncoCyte (OCX) Set to Announce Quarterly Earnings on Thursday

OncoCyte (NASDAQ:OCX) is scheduled to issue its quarterly earnings data after the market closes on Thursday, August 8th. Persons interested in listening to the company’s earnings conference call can do so using this link.

OncoCyte (NASDAQ:OCX) last issued its quarterly earnings data on Wednesday, May 15th. The company reported ($1.13) EPS for the quarter. The company had revenue of $0.18 million during the quarter. OncoCyte had a negative return on equity of 135.45% and a negative net margin of 2,905.14%.

OncoCyte Trading Up 6.3 %

Shares of OCX traded up $0.18 during trading hours on Tuesday, reaching $3.05. 9,436 shares of the company traded hands, compared to its average volume of 42,827. OncoCyte has a 12 month low of $2.08 and a 12 month high of $4.34. The company’s fifty day moving average price is $2.94 and its two-hundred day moving average price is $2.92.

Analyst Ratings Changes

Several research firms have weighed in on OCX. StockNews.com began coverage on OncoCyte in a research report on Sunday. They set a “sell” rating on the stock. Stephens reiterated an “equal weight” rating and issued a $4.00 price objective on shares of OncoCyte in a report on Wednesday, April 17th. Benchmark restated a “speculative buy” rating and set a $5.00 target price on shares of OncoCyte in a report on Monday, April 15th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $4.25 price target on shares of OncoCyte in a research note on Thursday, May 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, OncoCyte currently has a consensus rating of “Hold” and an average target price of $4.06.

OncoCyte Company Profile

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.